Home LiteratureArticle Details
PMID: 10906221 Published · ppublish English Journal Article Research Support, Non-U.S. Gov't

Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.

Journal of virology ·Vol. 74 ·No. 16 ·2000-08-00 ·Pages 7651-5

Ramírez JC, Gherardi MM, Rodríguez D, Esteban M

Abstract

A problem associated with the use of vaccinia virus recombinants as vaccines is the existence of a large human population with preexisting immunity to the vector. Here we showed that after a booster with attenuated recombinant modified vaccinia virus Ankara (rMVA), higher humoral and cellular immune responses to foreign antigens (human immunodeficiency virus type 1 Env and beta-galactosidase) were found in mice preimmunized with rMVA than in mice primed with the virulent Western Reserve strain and boosted with rMVA. This enhancement correlated with higher levels of expression of foreign antigens after the booster.

MeSH Terms
Animals Gene Products, env/immunology Genetic Vectors/immunology HIV-1/genetics,metabolism Humans Immunization, Secondary Mice Mice, Inbred BALB C Vaccines, Attenuated/immunology Vaccines, Synthetic/immunology Vaccinia virus/genetics,immunology,pathogenicity Viral Vaccines/immunology Virulence beta-Galactosidase/immunology
Chemicals
Gene Products, env Vaccines, Attenuated Vaccines, Synthetic Viral Vaccines beta-Galactosidase
Authors & Affiliations
4 authors, click to expand affiliations / ORCID
Ramírez J C
Department of Molecular and Cellular Biology, Centro Nacional de Biotecnología, CSIC, Campus Universidad Autónoma, E-28049 Madrid, Spain.
Gherardi M M
Rodríguez D
Esteban M
References (23)
23 references, click to expand
  1. Successful vaccination with a polyvalent live vector despite existing immunity to an expressed antigen.
    Nature. 1988 Sep 15;335(6187):259-62 PMID: 2842693
  2. Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.
    J Virol. 1988 May;62(5):1530-4 PMID: 2833606
  3. Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.
    Lancet. 1991 Mar 9;337(8741):567-72 PMID: 1671940
  4. Overcoming inhibition of antibody responses to a malaria recombinant vaccinia virus caused by prior exposure to wild type virus.
    Vaccine. 1991 Jul;9(7):470-2 PMID: 1716807
  5. Enhanced immunity to human immunodeficiency virus (HIV) envelope elicited by a combined vaccine regimen consisting of priming with a vaccinia recombinant expressing HIV envelope and boosting with gp160 protein.
    Proc Natl Acad Sci U S A. 1993 Mar 1;90(5):1882-6 PMID: 8446603
  6. Class I major histocompatibility complex-restricted cytotoxic T cell responses to vaccinia virus in humans.
    J Gen Virol. 1993 Apr;74 ( Pt 4):751-4 PMID: 8468558
  7. Vaccination with two different vaccinia recombinant viruses: long-term inhibition of secondary vaccination.
    Vaccine. 1993;11(11):1154-8 PMID: 8249436
  8. Molecular analysis of the same HIV peptide functionally binding to both a class I and a class II MHC molecule.
    J Immunol. 1995 Feb 15;154(4):1973-86 PMID: 7530749
  9. Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates.
    Adv Exp Med Biol. 1996;397:7-13 PMID: 8718576
  10. Genetically engineered poxviruses for recombinant gene expression, vaccination, and safety.
    Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11341-8 PMID: 8876137
  11. Recombinant modified vaccinia virus Ankara-simian immunodeficiency virus gag pol elicits cytotoxic T lymphocytes in rhesus monkeys detected by a major histocompatibility complex class I/peptide tetramer.
    Proc Natl Acad Sci U S A. 1998 Aug 18;95(17):10112-6 PMID: 9707609
  12. Mucosal and systemic immune responses induced after oral delivery of vaccinia virus recombinants.
    Vaccine. 1999 Mar 5;17(9-10):1074-83 PMID: 10195617
  13. Mucosal vaccination overcomes the barrier to recombinant vaccinia immunization caused by preexisting poxvirus immunity.
    Proc Natl Acad Sci U S A. 1999 Apr 13;96(8):4512-7 PMID: 10200293
  14. IL-12 delivery from recombinant vaccinia virus attenuates the vector and enhances the cellular immune response against HIV-1 Env in a dose-dependent manner.
    J Immunol. 1999 Jun 1;162(11):6724-33 PMID: 10352291
  15. Induction of CD8+ T cells using heterologous prime-boost immunisation strategies.
    Immunol Rev. 1999 Aug;170:29-38 PMID: 10566139
  16. Effect of virulence on immunogenicity of single and double vaccinia virus recombinants expressing differently immunogenic antigens: antibody-response inhibition induced by immunization with a mixture of recombinants differing in virulence.
    J Gen Virol. 1999 Nov;80 ( Pt 11):2901-8 PMID: 10580051
  17. Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.
    J Virol. 2000 Jan;74(2):923-33 PMID: 10623755
  18. [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].
    Zentralbl Bakteriol B. 1978 Dec;167(5-6):375-90 PMID: 219640
  19. Construction of live vaccines using genetically engineered poxviruses: biological activity of vaccinia virus recombinants expressing the hepatitis B virus surface antigen and the herpes simplex virus glycoprotein D.
    Proc Natl Acad Sci U S A. 1984 Jan;81(1):193-7 PMID: 6320164
  20. Vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D prevents latent herpes in mice.
    Science. 1985 May 10;228(4700):737-40 PMID: 2986288
  21. Recombinant vaccinia virus: immunization against multiple pathogens.
    Science. 1985 Sep 6;229(4717):981-4 PMID: 2992092
  22. Expression of the firefly luciferase gene in vaccinia virus: a highly sensitive gene marker to follow virus dissemination in tissues of infected animals.
    Proc Natl Acad Sci U S A. 1988 Mar;85(5):1667-71 PMID: 3422754
  23. Humoral immune response elicited by highly attenuated variants of vaccinia virus and by an attenuated recombinant expressing HIV-1 envelope protein.
    Virology. 1989 Nov;173(1):323-9 PMID: 2510402
Article Info
Journal
Journal of virology
Abbr.
J Virol
ISSN
0022-538X
DOI
10.1128/jvi.74.16.7651-7655.2000
Published
2000-08-00
Pages
7651-5
Language
English
Region
United States
NLM ID
0113724
PMCID
PMC112288
Subset
IM
External Links
PubMed source DOI: 10.1128/jvi.74.16.7651-7655.2000 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2